

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199655277 B2**
(10) Patent No. **708111**

(54) Title
Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1 protein

(51)⁶ International Patent Classification(s)
C12N 015/37 C07K 016/08
A61K 039/12 C12N 007/00
A61K 048/00 C12N 015/81
C07K 014/025

(21) Application No: **199655277**

(22) Application Date: **1996.03.26**

(87) WIPO No: **WO96/30520**

(30) Priority Data

(31) Number	(32) Date	(33) Country
08/413572	1995.03.30	US
08/413571	1995.03.30	US

(43) Publication Date : **1996.10.16**

(43) Publication Journal Date : **1996.12.05**

(44) Accepted Journal Date : **1999.07.29**

(71) Applicant(s)
Merck and Co., Inc.

(72) Inventor(s)
Kathryn J Hofmann; Kathrin U Jansen; Michael P. Neeper; Joseph G Joyce; Hugh A George ; E. Dale Lehman

(74) Agent/Attorney
SPRUSON and FERGUSON,GPO Box 3898,SYDNEY NSW 2001

(56) Related Art
WO 94/20137
WO 93/02184
J. GEN. VIROLOGY, VOL.75, 1994, PP.2271-2276

OPI DATE 16/10/96 APPLN. ID 55277/96
AOJP DATE 05/12/96 PCT NUMBER PCT/US96/04117



AU9655277

I (PCT)

(51) International Patent Classification ⁶ : C12N 15/37, 15/81, C07K 16/08, C12N 7/00, C07K 14/025, A61K 39/12, A61K 48/00 SEARCH QUALITY ASSURANCE 48/00		A2	(11) International Publication Number: WO 96/30520
(21) International Application Number: PCT/US96/04117		(43) International Publication Date: 3 October 1996 (03.10.96)	
(22) International Filing Date: 26 March 1996 (26.03.96)		(US). JOYCE, Joseph, G. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). GEORGE, Hugh, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). LEHMAN, E., Dale [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	
(30) Priority Data: 08/413,572 30 March 1995 (30.03.95) US 08/413,571 30 March 1995 (30.03.95) US		(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	
(60) Parent Applications or Grants (63) Related by Continuation US 08/413,572 (CON) Filed on 30 March 1995 (30.03.95) US 08/413,571 (CON) Filed on 30 March 1995 (30.03.95)		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		Published Without international search report and to be republished upon receipt of that report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): HOFMANN, Kathryn, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). JANSEN, Kathrin, U. [DE/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). NEEPER, Michael, P. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			

(54) Title: SYNTHETIC HPV6/11 HYBRID L1 DNA ENCODING HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN

(57) Abstract

The present invention is directed to a synthetic DNA molecule encoding purified human papillomavirus type 11 L1 protein and derivatives thereof.

TITLE OF THE INVENTION

SYNTHETIC HPV6/11 HYBRID L1 DNA ENCODING HUMAN
PAPILLOMAVIRUS TYPE 11 L1 PROTEIN

5 CROSS-RELATED TO OTHER APPLICATIONS

This is a continuation of U.S. Serial No. 08/413,572 filed
March 30, 1995, now pending, and a continuation of U.S. Serial No.
~~08/413,571~~ filed March 30, 1995, now pending.

10 FIELD OF THE INVENTION

The present invention is directed to a synthetic DNA
molecule encoding purified human papillomavirus type 11 L1 protein
and derivatives thereof.

15 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic of the construction of the HPV6/11
hybrid L1 gene using synthetic oligonucleotides.

Figure 2 shows the nucleotide sequence of the HPV6/11
hybrid, published HPV6a and published HPV11 L1 genes.

20 Figure 3 shows the bidirectional yeast expression vector
pGAL1-10 used to express papillomavirus L1 capsid proteins.

Figure 4 is a Northern analysis of HPV11 L1 mRNA from
yeast.

25 Figure 5 shows expression of HPV11 L1 protein in yeast by
Western analysis (immunoblot).

Figure 6 shows ELISA reactivities of HPV11 L1 VLPs
expressed from wild-type (wt) HPV11 compared to HPV6/11 hybrid
DNA.

30 Figure 7 is an electron micrograph of HPV11 L1 VLPs
expressed in yeast.

Figure 8 shows the nucleotide sequence of the HPV6/11
hybrid gene.

- 2 -

BACKGROUND OF THE INVENTION

Papillomavirus (PV) infections occur in a variety of animals, including humans, sheep, dogs, cats, rabbits, monkeys, snakes and cows. Papillomaviruses infect epithelial cells, generally inducing benign epithelial or fibroepithelial tumors at the site of infection. PV are species specific infective agents; a human papillomavirus cannot infect a nonhuman animal.

Papillomaviruses may be classified into distinct groups based on the host that they infect. Human papillomaviruses (HPV) are further classified into more than 70 types based on DNA sequence homology. PV types appear to be type-specific immunogens in that a neutralizing immunity to infection by one type of papillomavirus does not confer immunity against another type of papillomavirus.

In humans, different HPV types cause distinct diseases. HPV types 1, 2, 3, 4, 7, 10 and 26-29 cause benign warts in both normal and immunocompromised individuals. HPV types 5, 8, 9, 12, 14, 15, 17, 19-25, 36 and 46-50 cause flat lesions in immunocompromised individuals. HPV types 6, 11, 34, 39, 41-44 and 51-55 cause nonmalignant condylomata of the genital or respiratory mucosa. HPV types 16, 18, 31, 33, 35, 45, and 58 cause epithelial dysplasia of the genital mucosa and are associated with the majority of *in situ* and invasive carcinomas of the cervix, vagina, vulva and anal canal.

Papillomaviruses are small (50-60 nm), nonenveloped, icosahedral DNA viruses that encode for up to eight early and two late genes. The open reading frames (ORFs) of the virus genomes are designated E1 to E8 and L1 and L2, where "E" denotes early and "L" denotes late. L1 and L2 code for virus capsid proteins. The early (E) genes are associated with functions such as viral replication, transcriptional regulation and cellular transformation.

The L1 protein is the major capsid protein and has a molecular weight of 55-60 kDa. L2 protein is a minor capsid protein which has a predicted molecular weight of 55-60 kDa and an apparent molecular weight of 75-100 kDa as determined by polyacrylamide gel electrophoresis. Immunological data suggest that most of the L2 protein

- 3 -

is internal to the L1 protein within the viral capsomere. The L1 ORF is highly conserved among different papillomaviruses. The L2 proteins are less conserved among different papillomaviruses.

5 The L1 and L2 genes have been identified as good targets for immunoprophylaxis. Some of the early genes have also been demonstrated to be potential targets of vaccine development. Studies in the cottontail rabbit papillomavirus (CRPV) and bovine papillomavirus (BPV) systems have shown that immunizations with recombinant L1 and/or L2 proteins (produced in bacteria or by using vaccinia vectors)
10 protected animals from viral infection. Expression of papillomavirus L1 genes in baculovirus expression systems or using vaccinia vectors resulted in the assembly of virus-like particles (VLP) which have been used to induce high-titer virus-neutralizing antibody responses that correlate with protection from viral challenge. Furthermore, the L1 and
15 L2 genes have been used to generate vaccines for the prevention and treatment of papillomavirus infections in animals.

The development and commercialization of prophylactic and therapeutic vaccines for PV infection and disease containing L1 protein, L1 + L2 proteins, or modified L1 or L1 + L2 proteins has been hindered
20 by the lack of large quantities of purified virus and purified protein. Because PV is not readily cultivated *in vitro*, it is difficult to produce the required amounts of L1 and L2 protein by *in vitro* propagation of PV. The resultant supply problems make it difficult to characterize PV and PV proteins. Accordingly, it would be useful to develop a readily
25 renewable source of crude PV proteins, especially PV L1 and L2 proteins or modified L1 and L2 proteins. It would also be useful to develop methods of purifying large quantities of the crude papillomavirus proteins to levels of purity suitable for immunological studies and vaccine development. It would also be useful to produce large quantities of
30 papillomavirus proteins having the immunity-conferring properties of the native proteins, such as the conformation of the native protein. In addition, it would be useful to develop methods of analyzing the PV proteins and methods of determining the relative purity of the proteins as well as compositions containing the proteins. Such highly purified

- 4 -

proteins would also be useful in the preparation of a variety of reagents useful in the study of PV infection; such reagents include but are not limited to polyclonal antibodies, monoclonal antibodies, and analytical standards.

- 5 HPV6 and 11 are causative agents for ~90% of benign genital warts and are only rarely associated with malignancies (Gissmann *et al.*, 1983, *PNAS* 80, 560-563). HPV6a is considered to be the most abundant HPV6 subtype in condyloma accuminata (Brown, D. B., *et al.*, *J. Clin. Microbiol.* 31:1667-1673). Office visits for genital warts
- 10 (condyloma accuminatum or planum) have been on the rise in recent years. It is estimated that ~ 10% of the general population (ages 15-49) have genital-tract HPV infections (Koutsky *et al.* 1988, *Epidemiol. Rev.* 10, 122-163). While the majority of condylomata is associated with HPV6, in the case of laryngeal papillomatosis, HPV11 is the dominant
- 15 type. HPV11 replication in the epithelial cells of the respiratory tract stimulates the proliferation of these cells which can lead to isolated lesions of minor clinical relevance or to multiple spreading lesions and recurring disease. Recurrent respiratory papillomatosis, a disease which more often afflicts the juvenile population, can be a life-threatening
- 20 disease by causing obstructions in the respiratory tract. Recently, an animal model which allows the replication of infectious HPV11, has been developed (Kreider *et al.* 1985, *Nature* 317, 639-640; Kreider *et al.* 1987, *J. Virol.* 61, 590-593). The model enabled the identification of conformational neutralizing epitopes on native virions and baculovirus-
- 25 expressed VLPs using monoclonal antibodies (Christensen *et al.* 1990, *J. Virol.* 64, 5678-5681; Christensen and Kreider 1991, *Virus Res.* 21, 169-179; Christensen and Kreider 1993, *Virus Res.* 28, 195-202; Christensen *et al.* 1994, 75, 2271-2276).

- 30 Virus-like particles containing HPV11 L1 protein have been expressed in both insect and mammalian cell systems. Expression of VLPs in yeast cells offers the advantages of being cost-effective and easily adapted to large-scale growth in fermenters. However, the HPV11 L1 protein is expressed at low levels in yeast cells. This was observed to be a result of truncation of the HPV11 L1 mRNA. In contrast, the HPV6

L1 gene is transcribed as full-length mRNA and is expressed to high levels. By modifying the HPV6 L1 DNA to encode the HPV11 L1 protein, it is possible to facilitate the transcription of full-length mRNA resulting in increased HPV11 L1 protein expression. The present invention provides an HPV6/11 hybrid L1 gene sequence as well
5 as a method for the construction of the HPV6/11 hybrid L1 gene using synthetic oligonucleotides. The hybrid gene was designed using the HPV6a L1 sequence (Hofmann, K. J., *et al.*, 1995, *Virology*, accepted for publication) but contains the minimal number of base changes necessary to encode the HPV11 L1 protein. Unlike the wild-type HPV11 L1 gene, the HPV6/11 hybrid gene does not contain yeast-recognized
10 internal transcription termination signals; as a result full-length HPV6/11 mRNA is produced and expression of HPV11 L1 protein is increased.

The present invention is directed to highly purified PV L1 protein. The invention also comprises methods by which recombinant papillomavirus proteins having the immunity-conferring properties of the native papillomavirus proteins are produced and
15 purified. The present invention is directed to the production of prophylactic and therapeutic vaccines for papillomavirus infection. Electron microscopy and binding to conformational antibodies demonstrate that the recombinant proteins of the present invention are capable of forming virus-like particles.

Summary of the Invention

20 The present invention provides an isolated and purified DNA molecule encoding purified human papillomavirus type 11 L1 protein, the DNA molecule being free of internal transcription termination signals which are recognised by yeast.

Detailed Description of the Invention

A first aspect of the present invention is directed to an isolated and purified DNA
25 molecule encoding purified human papillomavirus type 11 L1 protein, the DNA molecule being free of internal transcription termination signals which are recognised by yeast. Various embodiments of the invention include but are not limited to recombinant HPV DNA molecules, RNA complementary to the recombinant HPV DNA molecules, proteins encoded by the recombinant DNA molecules, antibodies to the

- 6 -

recombinant DNA molecules and related proteins, compositions comprising the DNA, RNA, proteins or antibodies, methods of using the DNA, RNA, proteins or antibodies as well as derivatives thereof. Such derivatives include but are not limited to peptides and proteins encoded
5 by the DNA, antibodies to the DNA or antibodies to the proteins encoded by the DNA, vaccines comprising the DNA or vaccines comprising proteins encoded by the DNA, immunological compositions comprising the DNA or the proteins encoded by the DNA, kits containing the DNA or RNA derived from the DNA or proteins encoded by the DNA.

10 HPV6 and 11 are causative agents for ~90% of benign genital warts and are only rarely associated with malignancies (Gissmann *et al.*, 1983, *PNAS* 80, 560-563). Office visits for genital warts (condyloma accuminatum or planum) have been on the rise in the last years and it is
15 estimated that ~ 10% of the general population (ages 15-49) have genital-tract HPV infections (Koutsky *et al.* 1988, *Epidemiol. Rev.* 10, 122-163). While the majority of condylomata is associated with HPV6, in the case of laryngeal papillomatosis, HPV11 is the dominant type. HPV11 replication in the epithelial cells of the respiratory tract stimulates the proliferation of these cells which can lead to isolated lesions of minor
20 clinical relevance or to multiple spreading lesions and recurring disease. Recurrent respiratory papillomatosis, a disease which more often afflicts the juvenile population, can be a life-threatening disease by causing obstructions in the respiratory tract. Recently, an animal model which allows the replication of infectious HPV11, has been developed (Kreider
25 *et al.* 1985, *Nature* 317, 639-640; Kreider *et al.* 1987, *J. Virol.* 61, 590-593). The model enabled the identification of conformational neutralizing epitopes on native virions and baculovirus-expressed VLPs using monoclonal antibodies (Christensen *et al.* 1990, *J. Virol* 64, 5678-5681; Christensen and Kreider 1991, *Virus-Res.* 21, 169-179; Christensen and Kreider 1993, *Virus Res.* 28, 195-202; Christensen *et al.* 1994, 75,
30 2271-2276).

The development and commercialization of prophylactic and therapeutic vaccines for PV infection and disease containing L1 protein, L1 + L2 proteins, or modified L1 or L1 + L2 proteins has been hindered

- 7 -

by the lack of large quantities of purified virus and purified protein. Because PV is not readily cultivated *in vitro*, it is difficult to produce the required amounts of L1 and L2 protein by *in vitro* propagation of PV. The difficulties associated with *in vitro* cultivation of PV also result in

5 difficulties in chemical, immunological and biological characterization of PV and PV proteins. Accordingly, it would be useful to develop a readily renewable source of crude PV proteins, especially PV L1 and L2 proteins or modified L1 and L2 proteins. It would also be useful to develop

10 methods of purifying large quantities of the crude papillomavirus proteins to levels of purity suitable for immunological studies and vaccine development. It would also be useful to produce large quantities of

15 papillomavirus proteins having the immunity-conferring properties of the native proteins, such as the conformation of the native protein. In addition, it would be useful to develop methods of analyzing the PV

20 proteins and methods of determining the relative purity of the proteins as well as compositions containing the proteins. Such highly purified proteins would also be useful in the preparation of a variety of reagents useful in the study of PV infection; such reagents include but are not limited to polyclonal antibodies, monoclonal antibodies, and analytical standards.

Virus-like particles containing HPV11 L1 protein have been expressed in both insect and mammalian cell systems. Expression of VLPs in yeast cells offers the advantages of being cost-effective and easily adapted to large-scale growth in fermenters. However, the HPV11

25 L1 protein is expressed at low levels in yeast cells. This was observed to be a result of truncation of the HPV11 L1 mRNA. In contrast, the HPV6 L1 gene is transcribed as full-length mRNA and is expressed to high levels. By modifying the HPV6 L1 DNA to encode the HPV11 L1 protein, it is possible to facilitate the transcription of full-length mRNA

30 resulting in increased HPV11 L1 protein expression. The present invention provides an HPV6/11 hybrid L1 gene as well as a method for the construction of the HPV6/11 hybrid L1 gene using synthetic oligonucleotides. The hybrid gene was designed using the HPV6a L1 sequence but contains the minimal number of base changes necessary to

- 8 -

encode the HPV11 L1 protein. Unlike the wild-type HPV11 L1 gene, the HPV6/11 hybrid gene does not contain yeast-recognized internal transcription termination signals, resulting in higher levels of mRNA and consequently increased HPV11 L1 protein expression.

- 5 Pharmaceutically useful compositions comprising the DNA or proteins encoded by the DNA may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a
- 10 pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein or VLP. Such compositions may contain proteins or VLP derived from more than one type of HPV.

- 15 Therapeutic or diagnostic compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose PV infections. The effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration. Generally, the compositions will be administered in dosages ranging from about 1 mcg to about 1 mg.

- 20 The pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral, mucosal, intravenous and intramuscular.

- 25 The vaccines of the invention comprise DNA, RNA or proteins encoded by the DNA that contain the antigenic determinants necessary to induce the formation of neutralizing antibodies in the host. Such vaccines are also safe enough to be administered without danger of clinical infection; do not have toxic side effects; can be administered by an effective route; are stable; and are compatible with vaccine carriers.

- 30 The vaccines may be administered by a variety of routes, such as orally, parenterally, subcutaneously, mucosally, intravenously or intramuscularly. The dosage administered may vary with the condition, sex, weight, and age of the individual; the route of administration; and the type PV of the vaccine. The vaccine may be used in dosage forms such

- 9 -

as capsules, suspensions, elixirs, or liquid solutions. The vaccine may be formulated with an immunologically acceptable carrier.

5 The vaccines are administered in therapeutically effective amounts, that is, in amounts sufficient to generate a immunologically protective response. The therapeutically effective amount may vary according to the type of PV. The vaccine may be administered in single or multiple doses.

10 The purified proteins of the present invention may be used in the formulation of immunogenic compositions. Such compositions, when introduced into a suitable host, are capable of inducing an immune response in the host.

15 The purified proteins of the invention or derivatives thereof may be used to generate antibodies. The term "antibody" as used herein includes both polyclonal and monoclonal antibodies, as well as fragments thereof, such as, Fv, Fab and F(ab)₂ fragments that are capable of binding antigen or hapten.

20 The proteins and protein derivatives of the present invention may be used to serotype HPV infection and HPV screening. The purified proteins, VLP and antibodies lend themselves to the formulation of kits suitable for the detection and serotyping of HPV. Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier may further comprise reagents such as L1 or L2 proteins or VLPs derived from recombinant HPV6/11 or other recombinant HPV type DNA molecules or antibodies
25 directed against these proteins. The carrier may also contain means for detection such as labeled antigen or enzyme substrates or the like.

The purified proteins are also useful as immunological standards, molecular weight markers and molecular size markers.

30 It is known that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences which contain alternative codons which code for the eventual translation of the identical amino acid. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also

- 10 -

included within the scope of this invention are mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.

It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally-occurring peptide. Methods of altering the DNA sequences include, but are not limited to site directed mutagenesis.

As used herein, a "functional derivative" of the HPV6/11 hybrid gene is a compound that possesses a biological activity (either functional or structural) that is substantially similar to the biological activity of HPV6/11. The term "functional derivatives" is intended to include the "fragments," "variants," "degenerate variants," "analogs" and "homologues" or to "chemical derivatives" of HPV6/11.

The term "analog" refers to a molecule substantially similar in function to either the entire HPV6/11 molecule or to a fragment thereof.

The cloned HPV6/11 DNA or fragments thereof obtained through the methods described herein may be recombinantly expressed by molecular cloning into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant HPV11. Techniques for such manipulations are fully described in Sambrook, J., *et al.*, *supra*, and are known in the art.

Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic genes in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells, fungal cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells or bacteria-fungal cells or bacteria-invertebrate cells. An appropriately constructed expression vector should contain: an origin of replication for autonomous replication

- 11 -

- in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which
- 5 causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses.

- A variety of mammalian expression vectors may be used to express HPV6/11 DNA or fragments thereof in mammalian cells.
- 10 Commercially available mammalian expression vectors which may be suitable for recombinant HPV6/11 DNA expression, include but are not limited to, pcDNA3 (Invitrogen), pMC1neo (Stratagene), pXT1 (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224),
- 15 pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and λ ZD35 (ATCC 37565).

- A variety of bacterial expression vectors may be used to express HPV6/11 DNA or fragments thereof in bacterial cells.
- 20 Commercially available bacterial expression vectors which may be suitable for recombinant HPV6/11 DNA expression include, but are not limited to pET11a (Novagen), lambda gt11 (Invitrogen), pcDNAII (Invitrogen), pKK223-3 (Pharmacia).

- A variety of fungal cell expression vectors may be used to express HPV6/11 or fragments thereof in fungal cells. Commercially
- 25 available fungal cell expression vectors which may be suitable for recombinant HPV6/11 DNA expression include but are not limited to pYES2 (Invitrogen), *Pichia* expression vector (Invitrogen) and *Hansenula* expression (Rhein Biotech, Dusseldorf, Germany).

- A variety of insect cell expression vectors may be used to
- 30 express HPV6/11 DNA or fragments thereof in insect cells.
- Commercially available insect cell expression vectors which may be suitable for recombinant expression of HPV6/11 DNA include but are not limited to pBlue Bac III (Invitrogen).

- 12 -

An expression vector containing HPV 6/11 DNA or fragments thereof may be used for expression of HPV11 proteins or fragments of HPV11 proteins in a cell, tissue, organ, or animal. Animal, as used herein, includes humans. Host cells may be prokaryotic or
5 eukaryotic, including but not limited to bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which may be suitable and
10 which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC
15 CCL 2), C1271 (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171).

The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, lipofection, protoplast fusion, and
20 electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce HPV11 protein. Identification of HPV11 expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-HPV11 antibodies.

25 Expression of HPV DNA fragments may also be performed using *in vitro* produced synthetic mRNA or native mRNA. Synthetic mRNA or mRNA isolated from cells expressing HPV6/11 hybrid DNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as
30 efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.

Following expression of HPV11 protein in a host cell, HPV11 protein may be recovered to provide HPV11 protein in purified

- 13 -

form. Several HPV11 purification procedures are available and suitable for use. As described herein, recombinant HPV11 protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange
5 chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography.

In addition, recombinant HPV11 protein may be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full length nascent
10 HPV11, or polypeptide fragments of HPV11. Monoclonal and polyclonal antibodies may be prepared according to a variety of methods known in the art. Monoclonal or monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for HPV11. Homogenous binding as
15 used herein refers to the ability of the antibody species to bind to a specific antigen or epitope.

It is apparent to those skilled in the art that the methods for producing monospecific antibodies may be utilized to produce antibodies specific for HPV polypeptide fragments, or full-length nascent HPV
20 polypeptides. Specifically, it is apparent to those skilled in the art that monospecific antibodies may be generated which are specific for the fully functional HPV proteins or fragments thereof.

The present invention is also directed to methods for screening for compounds which modulate the expression of DNA or
25 RNA encoding HPV as well as the function(s) of HPV11 protein *in vivo*. Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules. Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding HPV11, or the function of HPV11 protein. Compounds
30 that modulate the expression of DNA or RNA encoding HPV11 or the function of HPV11 protein may be detected by a variety of assays. The assay may be a simple "yes/no" assay to determine whether there is a change in expression or function. The assay may be made quantitative by

- 14 -

comparing the expression or function of a test sample with the levels of expression or function in a standard sample.

Kits containing HPV6/11 hybrid DNA, fragments of HPV6/11 hybrid DNA, antibodies to HPV6/11 DNA or HPV11 protein, HPV6/11 hybrid RNA or HPV11 protein may be prepared. Such kits are used to detect DNA which hybridizes to HPV6/11 DNA or to detect the presence of HPV11 protein or peptide fragments in a sample. Such characterization is useful for a variety of purposes including but not limited to forensic analyses and epidemiological studies.

Nucleotide sequences that are complementary to the HPV6/11 DNA sequence may be synthesized for antisense therapy. These antisense molecules may be DNA, stable derivatives of DNA such as phosphorothioates or methylphosphonates, RNA, stable derivatives of RNA such as 2'-O-alkylRNA, or other HPV6/11 antisense oligonucleotide mimetics. HPV6/11 antisense molecules may be introduced into cells by microinjection, liposome encapsulation or by expression from vectors harboring the antisense sequence. HPV6/11 antisense therapy may be particularly useful for the treatment of diseases where it is beneficial to reduce HPV11 activity.

The term "chemical derivative" describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.

Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages defined by routine testing in order to obtain optimal inhibition of the HPV11 or its activity while minimizing any potential toxicity. In addition, co-administration or sequential administration of other agents may be desirable.

Advantageously, compounds of the present invention may be administered in a single dose, or the total dosage may be administered in several divided doses. Furthermore, compounds for the present invention

- 15 -

may be administered via a variety of routes including but not limited to intranasally, transdermally, by suppository, orally, and the like.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents can be administered concurrently, or they each can be administered at separately staggered times.

The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed. A physician of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.

In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and may be administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrup, suppositories, gels and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth,

- 16 -

sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

For liquid forms the active drug component can be combined in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. Other dispersing agents which may be employed include glycerin and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.

Topical preparations containing the active drug component can be admixed with a variety of carrier materials well known in the art, such as, e.g., alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, PPG2 myristyl propionate, and the like, to form, e.g., alcoholic solutions, topical cleansers, cleansing creams, skin gels, skin lotions, and shampoos in cream or gel formulations.

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinyl-pyrrolidone, pyran copolymer, polyhydroxypropylmethacryl-amidephenol, polyhydroxy-ethylaspartamidephenol, or polyethyl-eneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving

- 17 -

controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydro-pyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

- 5 The following examples illustrate the present invention without, however, limiting the same thereto.

EXAMPLE 1

10 Construction of the Synthetic L1 Gene

The 1.5 kbp open reading frame of HPV11 L1 was constructed using synthetic DNA oligomers ordered from Midland Reagent Company. These oligomers were supplied containing 5' terminal phosphates. A total of 24 oligomers were required and are listed below:

15

#241-1

- 5'GAAGATCTCACAAAACAAAATGTGGCGGCCTAGCGACAGCA
CAGTATATGTGCCTCCTCCTAACCCGTATCCAAAGTTGTTGCC
ACGGATGCTTATGTTAAACGCACCAACATATTTTATCATGCCA
20 GCAGTTCTAGACTTCTTGCAGTGGGTCATCCTTATT 3' (SEQ ID
NO:1)

#2412

- 5'ATTCCATAAAAAAGGTTAACAAAAGTGTGTGCCAAAGGTGT
25 CAGGATATCAATACAGAGTATTTAAGGTGGTGTACCAGATCC
TAACAAATTTGCATTGCCTGACTCGTCTCTTTTATCCACAA
CACAACGTTTGGTATGGGCATGCATGT 3' (SEQ ID NO:2)

#241-3

- 30 5'ACATGCATGCACAGGCCTAGAGGTGGGCCGGGGACAGCCAT
TAGGTGTGGGTGTAAGTGGACATCCTTTACTAAATAAATATGA
TGATGTTGAAAATTCAGGGGGTTACGGTGGTAACCCTGGACAG
GATAACAGG 3' (SEQ ID NO:3)

- 18 -

#241-4

5'GTTAATGTAGGTATGGATTATAAACAAACACAATTATGCATG
GTTGGATGTGCCCCCCTTTGGGCGAGCATTGGGGTAAAGGTA
CACAGTGTAGTAATACATCTGTACAGAATGGTGACTGCCCCG 3'
5 (SEQ ID NO:4)

#241-5

5'CCTTAGAACTTATTACCAGTGTTATACAGGATGGCGATATGG
TTGACACAGGCTTTGGTGCTATGAATTTTGCTGATTTGCAGACC
10 AATAAATCAGATGTTCTCTTGACATATGTGGCACTGTA 3'
(SEQ ID NO:5)

#241-6

5'TGTAAATATCCAGATTATTTACAAATGGCTGCAGACCCATAT
15 GGTGATAGATTATTTTTTTATCTACGGAAGGAACAAATGTTTGC
CAGACATTTTTTTAACAGGGCTGGTACCCC 3'(SEQ ID NO:6)

#241-7

5'GGGGTACCGTGGGGGAACCTGTGCCTGATGATCTTTTAGTTA
20 AGGGTGGTAACAATCGCTCGTCTGTAGCGAGTAGTATATATGT
TCACACCCCAAGCGGCTCTTTGGTGTCTCTGAGGCACA 3'
(SEQ ID NO:7)

#241-8

5'ATTGTTTAATAAGCCATATTGGCTACAAAAAGCCCAGGGACA
25 TAACAATGGTATTTGTTGGGGTAATCATCTGTTTGTTACTGTGG
TAGATACCACACGCAGTACCAACATGA 3'(SEQ ID NO:8)

#241-9

5'CATTATGTGCATCCGTATCTAAATCTGCCACATACACCAATTC
30 TGATTATAAAGAGTACATGCGTCATGTGGAAGAGTTTGATTTA
CAATTTATTTTTCAATTATGTAGCATT 3'(SEQ ID NO:9)

- 19 -

#241-10

5'ACATTGCTGCTGAAGTAATGGCCTATATTCACACAATGAAT
CCCTCTGTTCTCGAGGACTGGAACCTTTGGGTTATCGCCTCCCCC
AAATGGTACACTCGAGCGG 3' (SEQ ID NO:10)

5

#241-11

5'CCGCTCGAGGATACCTATAGGTATGTGCAGTCACAGGCCATT
ACCTGTCAAAAGCCCACTCCTGAAAAGGAAAAGCAAGATCCCT
ATAAGGACATGAGTTTTTTGGGAGGTAAATTTAAAGAAAAGTT
10 TTCTAGTGAATTGGATCAGTTTCCTTT 3' (SEQ ID NO:11)

#241-12

5'GGGACGCAAGTTTTTTGTTACAAAGTGGATATAGGGGACGGAC
CTCTGCTCGTACCGGTATTAAGCGCCCTGCTGTTCCAAACCTT
15 CTACTGCCCTAAACGTAAGCGCACCAAACTAAAAAGTAAG
ATCTTC 3' (SEQ ID NO:12)

#241-13

5'GAAGATCTTACTTTTTAGTTTTGGTGCGCTTACGTTTAGGGGC
20 AGTAGAGGGTTTGGAACAGCAGGGCGCTTAATACCGGTACG
AGCAGAGGTCCGTCCCCTATATCCACTTTGTAACAAAACTTG
CGTCCCAAAGGAACTGATCCAATTC 3' (SEQ ID NO:13)

#241-14

25 5'ACTAGAAAACCTTTTCTTTTAAATTAACCTCCCAAAAACTCATG
TCCTTATAGGGATCTTGCTTTTCCTTTTCAGGAGTGGGCTTTTG
ACAGGTAATGGCCTGTGACTGCACATACCTATAGGTATCCTCG
AGCGG 3' (SEQ ID NO:14)

30 #241-15

5'CCGCTCGAGTGTACCATTTGGGGGAGGCGATAACCCAAAGTT
CCAGTCCTCGAGAACAGAGGGATTTCATTGTGTGAATATAGGCC
ATTACTTCAGCAGACAATGTAATGCTACATAATTGAAAAA 3'
(SEQ ID NO:15)

- 20 -

#241-16

5'TAAATTGTAAATCAAACCTCTTCCACATGACGCATGTACTCTTT
ATAATCAGAATTGGTGTATGTGGCAGATTTAGATACGGATGCA
CATAATGTCATGTTGGTACTGCGTGTG 3' (SEQ ID NO:16)

5

#241-17

5'GTATCTACCACAGTAACAAACAGATGATTACCCCAACAAATA
CCATTGTTATGTCCCTGGGCTTTTTGTAGCCAATATGGCTTATT
AAACAATTGTGCCTCAGAGGACACCAA 3' (SEQ ID NO:17)

10

#241-18

5'AGAGCCGCTTGGGGTGTGAACATATATACTACTCGCTACAGA
CGAGCGATTGTTACCACCCTTAACATAAAAGATCATCAGGCACA
GGTTCACCCACGGTACCCC 3' (SEQ ID NO:18)

15

#241-19

5'GGGGTACCAGCCCTGTTAAAAAATGTCTGGCAAACATTTGT
TCCTTCCGTAGATAAAAAAATAATCTATCACCATATGGGTCTG
CAGCCATTTGTAAATAATCTGGATATTTACATACAGTGCCACA
TATGTCAA 3' (SEQ ID NO:19)

20

#241-20

5'GAGGAACATCTGATTTATTGGTCTGCAAATCAGCAAAATTCA
TAGCACCAAAGCCTGTGTCAACCATATCGCCATCCTGTATAAC
ACTGGTAATAAGTTCTAAGGGCGGGCAGTCACCATTCTGT 3'
(SEQ ID NO:20)

25

#241-21

5'ACAGATGTATTACTACACTGTGTACCTTTACCCCAATGCTCGC
CCAAAGGGGGGGGCACATCCAACCATGCATAATTGTGTTTGT
ATAATCCATACCTACATTAACCCTGTTATCCTGTCCAGGGT 3'
(SEQ ID NO:21)

30

- 21 -

#241-22

5'TACCACCGTAACCCCTGAATTTTCAACATCATCATATTTATT
TAGTAAAGGATGTCCACTTACACCCACACCTAATGGCTGTCCC
CGGCCACCTCTAGGCCTGTGCATGCATGT 3'(SEQ ID NO:22)

5

#241-23

5'ACATGCATGCCCATACCAAACGTTGTGTTGTGGGATCAAAAA
GAGACGAGTCAGGCAATGCAAATTTGTTAGGATCTGGTAACAC
CACCTTAAATACTCTGTATTGATATCCTGACACCTTTGGCACAA
10 CAGTTTTGTTAACCTTTTTTATGGAATAATAAGGATGACCC 3'
(SEQ ID NO:23)

#241-24

5'ACTGCAAGAAGTCTAGAACTGCTGGCATGATAAAATATGTTG
15 GTGCGTTTAACATAAGCATCCGTGGCAACAACITTTGGATACAG
GGTTAGGAGGAGGCACATATACTGTGCTGTCTAGGCCGCCA
CATTTTGTTTTGTGAGATCTTC 3' (SEQ ID NO:24)

Oligomers forming complementary pairs (#241-1 and #241-
20 24, #241-2 and #241-23, #241-3 and #241-22, #241-4 and #241-21, #241-
5 and #241-20, #241-6 and #241-19, #241-7 and #241-18, #241-8 and
#241-17, #241-9 and #241-16, #241-10 and #241-15, #241-11 and #241-
14, #241-12 and #241-13- Figure 1) were annealed in separate tubes
containing 2.5 mM Tris, pH 7.5, 0.25 mM EDTA. Tubes were heated to
25 98°C for 4 min and then placed in 200 ml of 98°C water in a 250 ml
beaker to cool slowly. When the water cooled to room temperature, the
annealed pairs were added to tubes as designated: fragment A (oligomer
pairs #241-1 & 24, and -2 & 23); fragment B (#241-3 & 22, -4 & 21, -5 &
20, and -6 & 19); fragment C (#241-7 & 18, -8 & 17, -9 & 16 and -10 & 15)
30 and fragment D (#241-11 & 14 and -12 & 13). These oligomer pair mixes
were heated to 62°C for 2 min and then cooled slowly as before. The
contents of each tube were ligated overnight at 23°C using T4 DNA
ligase (Boehringer Mannheim, Inc.) and the reagents supplied by the
manufacturer.

- 22 -

After ligation, fragment B required PCR amplification to increase the amount of full-length product. This required ten cycles of 94°C, 1 min; 48°C, 1 min; 72°C, 1 min followed by 10 min at 72°C in an Applied Biosystems thermocycler using Boehringer Mannheim Taq

- 5 polymerase and the oligomer primers:
5'GGAATTCACATGCATGCACAGGCCTAG 3' (SEQ ID NO:25) and
5' GGAATTCGGGGTACCAGCCCTGTTAA 3' (SEQ ID NO:26).

- 10 The ligated products and the fragment B PCR product were digested with restriction enzymes (Boehringer Mannheim, Inc.) as follows: fragment A was digested with Bgl II and Sph I; fragment B, Sph I and Kpn I; fragment C, Kpn I and Xho I; and fragment D, Xho I and Bgl II. The digested fragments were separated on low melting point agarose (FMC BioProducts) gels and correctly sized fragments isolated
15 by excision of the band and digestion of the agarose using AgaraseTM (Boehringer Mannheim, Inc.) as recommended by the supplier. The fragments A, B and D were recovered by ethanol precipitation and then separately ligated into the vector pSP72 (Promega, Inc.) that had been similarly digested with restriction enzymes to match each fragment being
20 ligated.

The Kpn I Xho I digested fragment C was first ligated to the annealed oligomers

- 25 5'TCGAAGACTGGAACCTTTGGGTTATCGCCTCCCCCAAATGGTA
CAC 3'; (SEQ ID NO:27) and
5'TCGAGTGTACCATTGCGGGGAGGCGATAACCCAAAGTTCCAG
TCT3' (SEQ ID NO:28).

- 30 Fragment C was then recleaved with Xho I and the 450 bp KpnI XhoI fragment was ligated with the Kpn I, Xho I-digested pSP72 vector. The ligation mixes were used to transform *Escherichia coli* strain DH5 competent cells (Gibco BRL, Gaithersburg, MD). Transformants were screened for insert-containing clones by colony hybridization (J. Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd edition,

- 23 -

Cold Spring Harbor Laboratory Press, 1989). Plasmid DNA was isolated from the positive clones using a Wizard miniprep kit (Promega Corp.) and then sequenced using an Applied Biosystems 373A DNA Sequencer. Clones containing the correct DNA sequence for each of the four

5 fragments were digested as before to release the fragments from the pSP72 vector. The Kpn I, Xho I-digested fragment C was ligated with the Xho I, Bgl II-digested fragment D and Kpn I, Bgl II-cut pSP72 in a three-way ligation. The ligation products were then used to transform *E. coli*. Resulting transformants were sequenced and a clone of correct

10 sequence obtained (designated CD). The 750 bp Bgl II Kpn I insert of CD was released from the pSP72 vector and ligated with Bgl II, Sph I-digested fragment A and Sph I, Kpn I-digested fragment B in a three-way ligation as before except Bgl II was added to decrease undesired ligation products. The ligation products were separated on agarose gels,

15 the 1.5 kbp fragment was isolated, and was designated D361-1.

EXAMPLE 2

Comparison of Sequences

20 A comparison of the nucleotide sequence for the HPV6/11 hybrid, HPV6a and HPV11 L1 DNA sequences is shown in Figure 2. There are a total of 55 nucleotide substitutions made to the HPV 6 backbone sequence to convert it to a HPV11-encoding translation frame. In addition, three base pair insertions were added at #411-413 bp to

25 encode the additional amino acid (tyrosine¹³²) found in HPV11 but not HPV6. Together, these changes allow the type 11-specific, conformation-dependent, neutralizing monoclonal antibody (Chemicon 8740 MAb) to bind the L1 protein of the HPV6/11 L1 DNA expressed in yeast. This suggests that the protein from the HPV6/11 hybrid gene

30 appears to be indistinguishable immunologically from native HPV11.

Comparison of the HPV6/11 hybrid DNA sequence to the published HPV11 L1 sequence shows 194 base pair substitutions. There are a considerable number of substitutions relative to the wild type 11 L1

- 24 -

sequence, any combination of which or all changes in total may be what is responsible for the increased type 11 L1 protein expression in yeast.

EXAMPLE 3

5

DNA Sequencing of the L1 gene

The HPV6/11 L1 gene was sequenced using an Applied Biosystems DNA Sequencer #373A with dye terminator sequencing reactions (PRIZM™ Sequencing Kit) as specified by the manufacturer (ABI, Inc., Foster City, CA).

EXAMPLE 4

15 Construction of HPV6/11 L1, HPV11 L1 and HPV6 L1 Yeast Expression Vectors

The pGAL1-10 yeast expression vector was constructed by isolating a 1.4 kbp SphI fragment from a pUC18/bidirectional GAL promoter plasmid which contains the *Saccharomyces cerevisiae* divergent GAL1-GAL10 promoters from the plasmid pBM272 (provided by Mark Johnston, Washington University, St. Louis, MO). The divergent promoters are flanked on each side by a copy of the yeast ADH1 transcriptional terminator (Bennetzen, J.L. and Hall, B.D., 1982, *J. Biol. Chem.* 257: 3018-3025), a BamHI cloning site located between the GAL1 promoter and the first copy of the ADH1 transcriptional terminator and a SmaI cloning site located between the GAL10 promoter and the second copy of the ADH1 transcriptional terminator. A yeast shuttle vector consisting of pBR322, the yeast LEU2d gene (Erhart, E. and Hollenberg, C.P., 1983, *J. Bacteriol.* 156: 625-635) and the yeast 2u plasmid (gift of Benjamin Hall, University of Washington, Seattle, WA) (Broach, J.R. and Volkert, F.C., 1991, Circular DNA Plasmids of Yeasts, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York) was digested with SphI and ligated with the 1.4 kbp SphI divergent GAL promoter fragment resulting in pGAL1-10 (Figure 3).

35 The HPV6/11 hybrid L1 DNA encoding the HPV11 L1 protein (sample D361-1 from Example 1) contains a yeast non-translated

- 25 -

leader sequence (Kniskern, P.J. *et al.*, 1986, *Gene* 46: 135-141) immediately upstream to the HPV6/11 L1 initiating methionine codon. The pGAL1-10 plasmid was linearized with BamHI which cuts between the *GAL1* promoter and the *ADHI* transcription terminator and ligated with the 1.5 kbp, HPV6/11 L1 gene fragment (sample D361-1). *E. coli* DH5 (Gibco BRL, Inc.) transformants were screened and a pGAL1-10 plasmid containing the HPV6/11 L1 gene was isolated and designated as D362-1.

The wild-type HPV11 (wt-HPV11) DNA was cloned from a condyloma acuminatum lesion (kind gift of Dr. Darron Brown). Total human genomic DNA was extracted and digested with restriction endonucleases. The fraction containing wt-HPV11 DNA was ligated into an *E. coli* cloning vector to be used as a template for PCR. The wt-HPV11 L1 gene was amplified by PCR using Vent polymerase (New England Biolabs, Inc.), 10 cycles of amplification (94°C 1 min, 48°C 1 min, 72°C 1 min 45 sec), and the following oligonucleotide primers which contain flanking Bgl II sites (underlined):

sense primer: 5'-CTC AGA TCT CAC AAA ACA AAA TGT GGC
GGC CTA GCG ACA GCA CAG-3' (SEQ ID NO:29)
antisense primer: 5'-GAG AGA TCT TAC TTT TTG GTT TTG GTA
CGT TTT CG-3' (SEQ ID NO:30)

The sense primer introduces a yeast non-translated leader sequence (Kniskern, P.J. *et al.*, 1986, *Gene* 46: 135-141) immediately upstream to the wt-HPV11 L1 initiating methionine codon (highlighted in bold print). The 1.5 kbp wt-HPV11 L1 PCR product was digested with BglII, gel purified and ligated with the BamHI digested pGAL1-10 plasmid to yield plasmid, p329-1.

Total genomic DNA was extracted from an HPV6a-positive, condyloma acuminatum lesion (kind gift of Dr. Darron Brown). The HPV6a L1 gene was amplified by PCR using the biopsy sample DNA as a template, Vent polymerase (New England Biolabs, Inc.), 35 cycles of amplification (94°C 1 min, 48°C 1 min, 72°C 1 min 45 sec), the sense

- 26 -

primer listed above for PCR of wt-HPV11 L1 and an antisense primer with the sequence,

5' -GAG AGA TCT TAC CTT TTA GTT TTG GCG CGC TTA C-3'
(SEQ ID NO:31).

The 1.5 kbp HPV6a L1 PCR product was digested with BglII, gel purified and ligated with the BamHI digested pGAL1-10 plasmid to yield plasmid D128.

EXAMPLE 5

Preparation of Strain 1558

15 Step a: Preparation of Yeast Strain U9

Saccharomyces cerevisiae strain 2150-2-3 (*MAT α* , *leu2-04*, *ade1*, *cir*^o) was obtained from Dr. Leland Hartwell (University of Washington, Seattle, WA). Cells of strain 2150-2-3 were propagated overnight at 30°C in 5 mL of YEHD medium (Carty *et al.*, *J. Ind Micro* 2
20 (1987) 117-121). The cells were washed 3 times in sterile, distilled water, resuspended in 2 mL of sterile distilled water, and 0.1 mL of cell suspension was plated onto each of six 5-fluoro-orotic acid (FOA) plates in order to select for *ura3* mutants (Cold Spring Harbor Laboratory Manual for Yeast Genetics). The plates were incubated at 30°C. The
25 medium contained per 250 mL distilled water: 3.5 g, Difco Yeast Nitrogen Base without amino acids and ammonium sulfate; 0.5 g 5-Fluoro-orotic acid; 25 mg Uracil; and 10.0 g Dextrose.

The medium was sterilized by filtration through 0.2 μ m membranes and then mixed with 250 mL of 4% Bacto-Agar (Difco)
30 maintained at 50°C, 10 mL of a 1.2 mg/mL solution of adenine, and 5 mL of L-leucine solution (180 mg/ 50 mL). The resulting medium was dispensed at 20 mL per petri dish.

After 5 days of incubation, numerous colonies had appeared. Single colonies were isolated by restreaking colonies from the initial
35 FOA plates onto fresh FOA plates which were then incubated at 30°C. A

- 27 -

number of colonies from the second set of FOA plates were tested for the presence of the *ura3* mutation by replica-plating onto both YEHD plates and uracil-minus plates. The desired result was good growth on YEHD and no growth on uracil-minus medium. One isolate (U9) was obtained which showed these properties. It was stored as a frozen glycerol stock (strain #325) at -70°C for later use.

Step b: Preparation of a Vector for disruption of the Yeast *MNN9* gene

In order to prepare a vector for disruption of the *MNN9* gene, it was necessary to first clone the *MNN9* gene from *S. cerevisiae* genomic DNA. This was accomplished by standard Polymerase Chain Reaction (PCR) technology. A 5' sense primer and 3' antisense primer for PCR of the full-length *MNN9* coding sequence were designed based on the published sequence for the yeast *MNN9* gene (Zymogenetics: EPO Patent Application No. 88117834.7, Publication No. 0-314-096-A2). The following oligodeoxynucleotide primers containing flanking HindIII sites (underlined) were used:

sense primer: 5'-CTT AAA GCT TAT GTC ACT TTC TCT TGT ATC
G-3' (SEQ ID NO:32)

antisense primer: 5'-TGA TAA GCT TGC TCA ATG GTT CTC TTC
CTC-3'. (SEQ ID NO:33)

The initiating methionine codon for the *MNN9* gene is highlighted in bold print. The PCR was conducted using genomic DNA from *S. cerevisiae* strain JRY188 as template, Taq DNA polymerase (Perkin Elmer) and 25 cycles of amplification (94°C 1 min., 37°C 2 min., 72°C 3 min.). The resulting 1.2 kbp PCR fragment was digested with HindIII, gel-purified, and ligated with HindIII-digested, alkaline-phosphatase treated pUC13 (Pharmacia). The resulting plasmid was designated p1183.

- 28 -

In order to disrupt the *MNN9* gene with the yeast *URA3* gene, the plasmid pBR322-*URA3* (which contains the 1.1 Kbp *HindIII* fragment encoding the *S. cerevisiae URA3* gene subcloned into the *HindIII* site of pBR322) was digested with *HindIII* and the 1.1 kbp DNA fragment bearing the functional *URA3* gene was gel-purified, made blunt-ended with T4 DNA polymerase, and then ligated with *PmlI*-digested plasmid p1183 (*PmlI* cuts within the *MNN9* coding sequence). The resulting plasmid p1199 contains a disruption of the *MNN9* gene by the functional *URA3* gene.

10

Step c: Construction of U9-derivative strain 1372 containing disruption of *MNN9* gene

For disruption of the *MNN9* gene in strain U9 (#325), 30 µg of plasmid p1199 were digested with *HindIII* to create a linear *mn9::URA3* disruption cassette. Cells of strain 325 were transformed with the *HindIII*-digested p1199 DNA by the spheroplast method (Hinnen *et al.*, 1978, *Proc. Natl. Acad. Sci. USA* 75:1929-1933) and transformants were selected on a synthetic agar medium lacking uracil and containing 1.0 M sorbitol. The synthetic medium contained, per liter of distilled water: Agar, 20 g; Yeast nitrogen base w/o amino acids, 6.7 g; Adenine, 0.04 g; L-tyrosine, 0.05 g; Sorbitol, 182 g; Glucose, 20 g; and Leucine Minus Solution #2, 10 ml. Leucine Minus Solution #2 contains per liter of distilled water: L-arginine, 2 g; L-histidine, 1 g; L-Leucine, 6 g; L-Isoleucine, 6 g; L-lysine, 4 g; L-methionine, 1 g; L-phenylalanine, 6 g; L-threonine, 6 g; L-tryptophan, 4 g.

The plates were incubated at 30°C for five days at which time numerous colonies had appeared. Chromosomal DNA preparations were made from 10 colonies and then digested with *EcoRI* plus *HindIII*. The DNA digests were then evaluated by Southern blots (J. Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1989) using the 1.2 kbp *HindIII* fragment bearing the *MNN9* gene (isolated from plasmid p1199) as a probe. An isolate was identified (strain #1372) which showed the expected DNA

30

- 29 -

band shifts on the Southern blot as well as the extreme clumpiness typically shown by *mnn9* mutants.

Step d: Construction of a Vector for Disruption of Yeast *HIS3* Gene

- 5 In order to construct a disruption cassette in which the *S. cerevisiae HIS3* gene is disrupted by the *URA3* gene, the plasmid YEp6 (K. Struhl *et al.*, 1979, *Proc. Natl. Acad. Sci., USA* 76:1035) was digested with BamHI and the 1.7 kbp BamHI fragment bearing the *HIS3* gene was gel-purified, made blunt-ended with T4 DNA polymerase, and ligated
- 10 with pUC18 which had been previously digested with BamHI and treated with T4 DNA polymerase. The resulting plasmid (designated p1501 or pUC18-HIS3) was digested with NheI (which cuts in the *HIS3* coding sequence), and the vector fragment was gel-purified, made blunt-ended with T4 DNA polymerase, and then treated with calf intestine alkaline
- 15 phosphatase. The *URA3* gene was isolated from the plasmid pBR322-*URA3* by digestion with HindIII and the 1.1 kbp fragment bearing the *URA3* gene was gel-purified, made blunt-ended with T4 DNA polymerase, and ligated with the above pUC18-HIS3 NheI fragment. The resulting plasmid (designated pUC18-his3::*URA3* or p1505) contains a
- 20 disruption cassette in which the yeast *HIS3* gene is disrupted by the functional *URA3* gene.

Step e: Construction of Vector for Disruption of Yeast *PRB1* Gene by the *HIS3* Gene

- 25 Plasmid FP8ΔH bearing the *S. cerevisiae PRB1* gene was provided by Dr. E. Jones of Carnegie-Mellon Univ. (C. M. Moehle *et al.*, 1987, *Genetics* 115:255-263). It was digested with HindIII plus XhoI and the 3.2 kbp DNA fragment bearing the *PRB1* gene was gel-purified and made blunt-ended by treatment with T4 DNA polymerase. The plasmid
- 30 pUC18 was digested with BamHI, gel-purified and made blunt-ended by treatment with T4 DNA polymerase. The resulting vector fragment was ligated with the above *PRB1* gene fragment to yield the plasmid pUC18-*PRB1*. Plasmid YEp6, which contains the *HIS3* gene, was digested with BamHI. The resulting 1.7 kbp BamHI fragment bearing the functional

- 30 -

HIS3 gene was gel-purified and then made blunt-ended by treatment with T4 DNA polymerase. Plasmid pUC18-PRB1 was digested with EcoRV plus NcoI which cut within the *PRB1* coding sequence and removes the protease B active site and flanking sequence. The 5.7 kbp EcoRV-NcoI fragment bearing the residual 5' and 3'-portions of the *PRB1* coding sequence in pUC18 was gel-purified, made blunt-ended by treatment with T4 DNA polymerase, dephosphorylated with calf intestine alkaline phosphatase, and ligated with the blunt-ended *HIS3* fragment described above. The resulting plasmid (designated pUC18-prb1::HIS3, stock #1245) contains the functional *HIS3* gene in place of the portion of the *PRB1* gene which had been deleted above.

Step f: Construction of a U9-related Yeast Strain containing disruptions of both the *MNN9* and *PRB1* Genes

The U9-related strain 1372 which contains a *MNN9* gene disruption was described in Example 5c. Clonal isolates of strain 1372 were passaged on FOA plates (as described in Example 5a) to select *ura3* mutants. A number of *ura3* isolates of strain 1372 were obtained and one particular isolate (strain 12930-190-S1-1) was selected for subsequent disruption of the *HIS3* gene. The pUC18-his3::URA3 gene disruption vector (p1505) was digested with XbaI plus EcoRI to generate a linear *his3::URA3* disruption cassette and used for transformation of strain 12930-190-S1-1 by the lithium acetate method (Methods in Enzymology, 194:290 (1991)). Ura⁺ transformants were selected on synthetic agar medium lacking uracil, restreaked for clonal isolates on the same medium, and then replica-plated onto medium lacking either uracil or histidine to screen for those isolates that were both Ura⁺ and His⁻. One isolate (strain 12930-230-1) was selected for subsequent disruption of the *PRB1* gene. The *PRB1* gene disruption vector (pUC18-prb1::HIS3, stock #1245) was digested with SacI plus XbaI to generate a linear *prb1::HIS3* disruption cassette and used for transformation of strain 12930-230-1 by the lithium acetate method. His⁺ transformants were selected on agar medium lacking histidine and restreaked on the same medium for clonal isolates. Genomic DNA was prepared from a number of the resulting

- 31 -

His⁺ isolates, digested with EcoRI, and then electrophoresed on 0.8% agarose gels. Southern blot analyses were then performed using a radio-labeled 617 bp probe for the *PRB1* gene which had been prepared by PCR using the following oligodeoxynucleotide primers:

5

5' TGG TCA TCC CAA ATC TTG AAA 3' (SEQ ID NO:34); and

5' CAC CGT AGT GTT TGG AAG CGA 3' (SEQ ID NO:35)

10

Eleven isolates were obtained which showed the expected hybridization of the probe with a 2.44 kbp *prb1::HIS3* DNA fragment. This was in contrast to hybridization of the probe with the 1.59 kbp fragment for the wild-type *PRB1* gene. One of these isolates containing the desired *prb1::HIS3* disruption was selected for further use and was designated strain #1558.

15

EXAMPLE 6

Expression of HPV11 L1 and HPV6 L1 in Yeast

20

Plasmids D362-1 (pGAL1-10 + HPV6/11 L1), p329-1 (pGAL1-10 + wt-HPV11 L1), D128 (pGAL1-10 + HPV6 L1) and pGAL1-10 were used to transform *S. cerevisiae* strain #1558 (*MATa*, *leu2-04*, *prb1::HIS3*, *mn9::URA3*, *ade1*, *cir⁰*) by the spheroplast method (Hinnen *et al.*, 1978, *Proc. Natl. Acad. Sci. USA* 75, 1929-1933). The #1558 yeast strain transformed with plasmid D362-1 was designated as strain #1782. For RNA studies, yeast clonal isolates were grown at 30°C in YEH complex medium (Carty *et al.*, 1987, *J. Ind. Micro.* 2, 117-121) containing 0.1 M sorbitol and either 2% glucose or galactose for 26 hours. After harvesting the cells, yeast RNA was extracted using the hot acidic phenol method as described (Current Protocols in Molecular Biology, vol. 2, Current Protocols, 1993). For protein analysis, the identical isolates were grown at 30°C in YEH complex medium containing 0.1 M sorbitol, 2% glucose and 2% galactose for 70 hours. After harvesting the cells, the cell pellets were broken with glass beads

25

30

- 32 -

and cell lysates analyzed for the expression of HPV11 L1 or HPV6 L1 protein by immunoblot analysis.

EXAMPLE 7

5

Northern Blot Analysis of Yeast Expressed HPV L1 RNAs

Samples containing 10 µg of total RNA were denatured by treatment with glyoxal and DMSO (Current Protocols in Molecular Biology, vol. 1, Current Protocols, 1993) and electrophoresed through a
10 phosphate-buffered, 1.2% agarose gel. The RNA was transferred onto a nylon membrane and detected with a ³²P-labeled oligonucleotide that is complementary to both the HPV11 and HPV6 L1 DNA sequences.

The Northern blot is shown in Figure 4. No bands that correspond to the expected size for full-length HPV L1 RNA were
15 detected in the samples grown on glucose medium (lanes 1,3 and 5). This is expected since glucose represses transcription from the yeast GAL 1 promoter. In contrast, samples grown in galactose medium which induces transcription from the GAL1 promoter, show strong HPV L1 RNA signals. The HPV6 L1 was transcribed as a full-length RNA
20 species (lane 2) while the majority of the wild-type (wt)-HPV11 L1 was transcribed as a truncated form (lane 4). This result suggested that a yeast transcription termination signal is located within the wt-HPV11 L1 ORF but is not present in the HPV6 L1 sequence. The RNA transcribed from the HPV6/11 hybrid gene appears to be full-length (lane 6). No HPV
25 specific RNA is detected in the pGAL1-10 control yeast sample (lane 7).

EXAMPLE 8

Western Analysis of Yeast Expressed HPV L1 Proteins

30 Samples containing 20 µg of total cellular protein were electrophoresed through 10% Tris-Glycine gels (Novex, Inc.) under denaturing conditions and electroblotted onto nitrocellulose filters. L1 protein was immunodetected using rabbit antiserum raised against a *trpE*-HPV11 L1 fusion protein as primary antibody (Brown, D.R. *et al.*, 1994,
35 *Virology* 201:46-54) and horseradish peroxidase (HRP)-linked donkey

- 33 -

anti-rabbit IgG (Amersham, Inc.) as secondary antibody. The filters were processed using the chemiluminescent ECLTM Detection Kit (Amersham, Inc.). A 50-55 kDa L1 protein band was detected in all samples except the pGAL1-10 negative control (lane 4) (Figure 5).

- 5 Furthermore, the amount of HPV11 L1 protein expressed by the HPV6/11 hybrid gene (lane 3) appears to be ~10-fold greater than the amount of L1 protein expressed by either the wt-HPV11 gene (lane 2) or the HPV6 L1 gene (lane 1).

10

EXAMPLE 9

ELISA of Yeast Expressed HPV11 L1 VLPs

- An ELISA was used to determine relative amounts of VLPs produced from yeast clones expressing either wt-HPV11 or the HPV6/11 hybrid. The ELISA was also used to demonstrate that a conformational epitope giving rise to strongly neutralizing antibody responses was retained on the VLPs derived from the HPV6/11 hybrid DNA. This conformational epitope has been defined by monoclonal antibody H11.B2 (Christensen et al 1990, *J. Virol.* 64, 5678-5681) which is available from Chemicon International (Temecula, CA) as Chemicon Mab8740. Briefly, wells of ELISA plates (Maxisorb, Nunc Inc., Naperville, IL) were coated with decreasing amounts of total yeast protein containing the HPV6/11 (hybrid) or wt-HPV11 VLPs in 100 μ L PBS. CsCl-purified wt-HPV11 virions (a generous gift of Dr. D. Brown) and control yeast protein were used as controls. The plates were incubated overnight at 4°C before aspirating and blocking the plates with 250 μ L 10% dried milk (Carnation) in TTBS (50 mM Tris, pH 7.6, 150 mM NaCl, 0.1% Tween20) for 2 hrs at room temperature. The plates were washed once with PBS/0.1% Tween 20 before incubating the wells with 100 μ L of a 1:1000 dilution of the anti-HPV11 virion monoclonal antibody Chemicon MAB 8740 in 1% dried milk in TTBS for 1 hr at room temperature. Plates were washed 3 times with PBS/Tween 20 and then incubated with 100 μ L of anti-mouse IgG coupled to alkaline phosphatase (Kierkegard & Perry, Gaithersburg, MD) at a dilution of 1:1000 in 1% milk + TTBS for 1 hr at room temperature. Plates were again washed 3 times with

- 34 -

PBS/Tween 20 before adding 100 mcl of phosphatase substrate (p-nitrophenyl phosphate in diethanolamine buffer). Plates were incubated 30 min at room temperature. The reaction was stopped by addition of 50 mcl of 3N NaOH. Plates were read at 405 nm in an ELISA plate reader.

- 5 The average OD405 nm readings of 2 wells corrected against the background readings obtained from control yeast proteins were plotted against the total yeast protein in the wells and are shown in Figure 6. The HPV6/11 hybrid yeast clone produced more than 10 times the amount of native VLPs compared to the wt clone. In addition, the
- 10 strongly neutralizing epitope recognized by Chemicon Mab 8740 is displayed on these VLPs.

EXAMPLE 10

15 Electron Microscopic Studies

- For EM analysis (Structure Probe, West Chester, PA), an aliquot of each sample (crude clarified lysate or purified VLPs) was placed on 200-mesh carbon-coated copper grids. A drop of 2% phosphotungstic acid (PTA), pH 7.0 was placed on the grid for 20
- 20 seconds. The grids were allowed to air dry prior to transmission EM examination. All microscopy was done using a JEOL 100CX transmission electron microscope (JEOL USA, Inc.) at an accelerating voltage of 100 kV. The micrographs generated have a final magnification of 100,000x. As shown in Figure 7, VLPs were observed in the 45-55 nm
- 25 diameter size range in all HPV11 samples but not in yeast control samples.

EXAMPLE 11

30 Fermentation of HPV6/11 L1 (Strain #1782)

- Surface growth of a plate culture of strain 1782 was aseptically transferred to a leucine-free liquid medium containing (per L): 8.5 g Difco yeast nitrogen base without amino acids and ammonium sulfate; 0.2 g adenine; 0.2 g uracil; 10 g succinic acid; 5 g ammonium
- 35 sulfate; and 0.25 g L tyrosine; this medium was adjusted to pH 5.0-5.3

- 35 -

with NaOH prior to sterilization. After growth for 25 hr at 28°C, 250 rpm on a rotary shaker, frozen culture vials were prepared by adding sterile glycerol to a final concentration of 17% (w/v) prior to storage at -70°C (1 mL per cryovial). Inoculum for fermentation of strain 1782 was developed in the same medium (750 mL per 2-L flask) and was started by transferring the thawed contents of two frozen culture vials to the 2-L flasks and incubating at 28°C, 250 rpm on a rotary shaker for 25 hr. Fermentation of strain 1782 used a Chemap 23 L fermenter with a working volume of 18 L after inoculation. The production medium used contained (per L): 20 g Difco yeast extract; 10 g Sheffield HySoy peptone; 20 g glucose; 20 g galactose; the medium was adjusted to pH 5.3 prior to sterilization. The entire contents (500 mL) of the 2-L inoculum flask was transferred to the fermenter which was incubated at 28°C, 9 L air per min, 500 rpm, 3.5 psi pressure. Agitation was increased as needed to maintain dissolved oxygen levels of greater than 40% of saturation. Progress of the fermentation was monitored by offline glucose measurements (Beckman Glucose 2 Analyzer) and online mass spectrometry (Perkin-Elmer 1200). After 66 hr incubation, a cell density of 9.32 g dry cell weight per L was reached. The contents of two such fermentations (total 17.5 L broth) were pooled before cell recovery. The culture was concentrated by hollow fiber filtration (Amicon H5MP01-43 cartridge in an Amicon DC-10 filtration system) to ca. 2 L, diafiltered with 2 L phosphate-buffered saline, and concentrated further (to ca. 1 L) before dispensing into 500 mL centrifuge bottles. Cell pellets were collected by centrifugation at 8,000 rpm (Sorval GS3 rotor) for 20 min at 4°C. After decanting the supernatant, the pellets (total 358 g wet cells) were stored at -70°C until use.

EXAMPLE 12

Purification of Recombinant HPV Type 11 L1 Capsid Proteins

All steps were performed at 4°C unless noted.

Cells were stored frozen at -70°C. Frozen cells (wet weight = 180 g) were thawed at 20-23°C and resuspended in 900 mL "Breaking Buffer" (50 mM MOPS, pH 7.2, 500 mM NaCl, 1 mM CaCl₂). The

- 36 -

protease inhibitors AEBSF and pepstatin A were added to final concentrations of 1 mM and 1.7 μ M, respectively. The cell slurry was broken at a pressure of approximately 16,000 psi by 4 passes in a M110-Y Microfluidizer (Microfluidics Corp., Newton, MA). A sufficient
5 volume of 10% Triton X100[®] detergent (Pierce, Rockford, IL) was added to the broken cell slurry to bring the concentration of TX100 to 0.5%. The slurry was stirred for 20 hours. The Triton X100-treated lysate was centrifuged at 12,000 x g for 40 min to remove cellular debris. The supernatant liquid containing L1 protein was recovered.

10 The supernatant liquid was diafiltered against five volumes of 20 mM sodium phosphate, pH 7.2, 0.5 M NaCl using a 300K tangential flow membrane cassette (Filtron, Northborough, MA). The material retained by the membrane was shown by radioimmunoassay and western blotting to contain the L1 protein.

15 The retentate was applied to a high resolution affinity column (11.0 cm ID x 5.3 cm) of SP Spherox (M)[®] resin (IBF, Villeneuve-la-Garenne, France) equilibrated in 20 mM sodium phosphate, pH 7.2, 0.5 M NaCl. Following a wash with equilibration buffer and a step wash with 20 mM sodium phosphate, pH 7.2, 1.0 M
20 NaCl, the L1 protein was eluted with a step wash of 20 mM sodium phosphate, pH 7.2, 2.5 M NaCl. Fractions were collected during the washes and elution. Column fractions were assayed for total protein by the Bradford method. Fractions were then analyzed by western blotting and SDS-PAGE with colloidal Coomassie detection. Fractions were also
25 analyzed by radioimmunoassay.

SP Spherox fractions showing comparable purity and enrichment of L1 protein were pooled.

Final product was analyzed by western blotting and SDS-PAGE with colloidal Coomassie detection. The L1 protein was estimated
30 to be > 90% homogeneous. The identity of L1 protein was confirmed by western blotting. The final product was filtered aseptically through a 0.22 μ m membrane and stored at 4°C. This process resulted in a total of 100 mg protein.

- 37 -

Electron microscopy analysis is performed by Structure Probe (West Chester, PA). An aliquot of sample is placed on a 200 mesh carbon-coated copper grid. A drop of 2% phosphotungstic acid, pH 7.0 is placed on the grid for 20 seconds. The grid is allowed to air dry prior to
5 TEM examination. All microscopy is performed using a JEOL 100 CX transmission electron microscope (JEOL USA, Inc.) at an accelerating voltage of 100 kV. The micrographs generated have a final magnification of 100,000 x.

10 Bradford Assay for Total Protein

Total protein was assayed using a commercially available Coomassie Plus[®] kit (Pierce, Rockford, IL). Samples were diluted to appropriate levels in Milli-Q-H₂O. Volumes required were 0.1 mL and 1.0 mL for the standard and microassay protocols, respectively. For both
15 protocols, BSA (Pierce, Rockford, IL) was used to generate the standard curve. Assay was performed according to manufacturer's recommendations. Standard curves were plotted using CricketGraph[®] software on a Macintosh IIfx computer.

20 SDS-PAGE and Western Blot Assays

All gels, buffers, and electrophoretic apparatus were obtained from Novex (San Diego, CA) and were run according to manufacturer's recommendations. Briefly, samples were diluted to equal protein concentrations in Milli-Q-H₂O and mixed 1:1 with sample
25 incubation buffer containing 200 mM DTT. Samples were incubated 15 min at 100°C and loaded onto pre-cast 12% Tris-glycine gels. The samples were electrophoresed at 125V for 1 hr 45 min. Gels were developed by colloidal Coomassie staining using a commercially obtained kit (Integrated Separation Systems, Natick, MA).

30 For western blots, proteins were transferred to PVDF membranes at 25V for 40 min. Membranes were washed with Milli-Q-H₂O and air-dried. Primary antibody was polyclonal rabbit antiserum raised against a TrpE-HPV11L1 fusion protein (gift of Dr. D. Brown). The antibody solution was prepared by dilution of antiserum in blotting

- 38 -

5 buffer (5% non-fat milk in 6.25 mM Na phosphate, pH 7.2, 150 mM NaCl, 0.02% NaN₃). Incubation was for at least 1 hour at 20-23°C. The blot was washed for 1 min each in three changes of PBS (6.25 mM Na phosphate, pH 7.2, 150 mM NaCl). Secondary antibody solution was prepared by diluting goat anti-rabbit IgG alkaline phosphatase-linked conjugate antiserum (Pierce, Rockford, IL) in blotting buffer. Incubation proceeded under the same conditions for at least 1 hour. Blots were washed as before and detected using a 1 step NBT/BCIP substrate (Pierce, Rockford, IL).

10

EXAMPLE 13

Preparation of Immunogenic Compositions

15 Purified VLP's are formulated according to known methods, such as by the admixture of pharmaceutically acceptable carriers, stabilizers, or a vaccine adjuvant. The immunogenic VLP's of the present invention may be prepared for vaccine use by combining with a physiologically acceptable composition such as, e.g. PBS, saline or distilled water. The immunogenic VLP's are administered in a dosage
20 range of about 0.1 to 100 mcg, preferably about 1 to about 20 mcg, in order to obtain the desired immunogenic effect. The amount of VLP per formulation may vary according to a variety of factors, including but not limited to the individual's condition, weight, age and sex. Administration of the VLP formulation may be by a variety of routes, including but not
25 limited to oral, subcutaneous, topical, mucosal and intramuscular. Such VLP formulations may be comprised of a single type of VLP (i.e., VLP from HPV11) or a mixture of VLP's (i.e., VLP's from HPV6, HPV11, HPV16 and HPV18).

30 An antimicrobial preservative, e.g. thimerosal, optionally may be present. The immunogenic antigens of the present invention may be employed, if desired, in combination with vaccine stabilizers and vaccine adjuvants. Typical stabilizers are specific compounds, e.g. polyanions such as heparin, inositol hexasulfate, sulfated beta-cyclodextrin, less specific excipients, e.g. amino acids, sorbitol, mannitol,
35 xylitol, glycerol, sucrose, dextrose, trehalose, and variations in solution

- 39 -

conditions, e.g. neutral pH, high ionic strength (ca. 0.5-2.0 M salts), divalent cations (Ca^{2+} , Mg^{2+}). Examples of adjuvants are $\text{Al}(\text{OH})_3$ and $\text{Al}(\text{PO}_4)$. The vaccine of the present invention may be stored under refrigeration or in lyophilized form.

5

EXAMPLE 14

Preparation of Antibodies to VLP

Purified VLP are used to generate antibodies. The term
10 "antibody" as used herein includes both polyclonal and monoclonal antibodies as well as fragments thereof, such as Fv, Fab and $\text{F}(\text{ab})_2$ fragments that are capable of binding antigen or hapten. The antibodies are used in a variety of ways, including but not limited to the purification of recombinant VLP, the purification of native L1 or L2 proteins, and
15 kits. Kits would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further comprise reagents such as the anti-VLP antibody or the VLP suitable for detecting HPV or fragments of HPV or antibodies to HPV. The carrier may also contain means for detection such as labeled antigen or enzyme
20 substrates or the like. The antibodies or VLP or kits are useful for a variety of purposes, including but not limited to forensic analyses and epidemiological studies.


The claims defining the invention are as follows:

1. An isolated and purified DNA molecule encoding human papillomavirus type 11 L1 protein, the DNA molecule being free of internal transcription termination signals which are recognised by yeast.
- 5 2. The DNA molecule of claim 1 having the sequence shown in Figure 8.
3. An expression vector comprising the DNA molecule of claim 1.
4. An expression vector comprising the DNA molecule of claim 2.
5. The express vector of claim 4 which is D361-1.
6. Compositions comprised of the DNA molecule of claim -1 or RNA
10 complementary to the DNA molecule of claim 1.
7. A nucleic acid encoding human papillomavirus type 11 L1 protein, the nucleic acid molecule being free from internal transcription termination signals which are recognised by yeast.
8. An isolated and purified DNA molecule encoding human papillomavirus type
15 11 L1 protein, substantially as hereinbefore described with reference to any one of the examples.
9. A composition comprising the molecule as claimed in claim 8, or RNA complementary to that molecule.

Dated 26 May, 1999
Merck & Co., Inc.

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON

1/12

OLIGOMER DESIGNATIONS:
(#241-1)

FRAGMENT ASSEMBLY:




FIG.1

SUBSTITUTE SHEET (RULE 26)

2/12

	10	20	30	40	50	
Lowy-16L1	1	ATGTCCTTT	GGCTGCCTAG	TGAGGCCACT	GTCTACTTGC	CTCCTGTCCC 50
hpv1611.gb	1	ATGTCCTTT	GGCTGCCTAG	TGAGGCCACT	GTCTACTTGC	CTCCTGTCCC 50
hpv1611.mrl	1	ATGTCCTTT	GGCTGCCTAG	TGAGGCCACT	GTCTACTTGC	CTCCTGTCCC 50
	60	70	80	90	100	
Lowy-16L1	51	AGTATCTAAG	GTTGTAAGCA	CGGATGAATA	TGTTGCACGC	ACAAACATAT 100
hpv1611.gb	51	AGTATCTAAG	GTTGTAAGCA	CGGATGAATA	TGTTGCACGC	ACAAACATAT 100
hpv1611.mrl	51	AGTATCTAAG	GTTGTAAGCA	CGGATGAATA	TGTTGCACGC	ACAAACATAT 100
	110	120	130	140	150	
Lowy-16L1	101	ATTATCATGC	AGGAACATCC	AGACTACTTG	CAGTTGGACA	TCCCTATTTT 150
hpv1611.gb	101	ATTATCATGC	AGGAACATCC	AGACTACTTG	CAGTTGGACA	TCCCTATTTT 150
hpv1611.mrl	101	ATTATCATGC	AGGAACATCC	AGACTACTTG	CAGTTGGACA	TCCCTATTTT 150
	160	170	180	190	200	
Lowy-16L1	151	CCTATTAATA	AACCTAACAA	TAACAAAATA	TTAGTTCCTA	AAGTATCAGG 200
hpv1611.gb	151	CCTATTAATA	AACCTAACAA	TAACAAAATA	TTAGTTCCTA	AAGTATCAGG 200
hpv1611.mrl	151	CCTATTAATA	AACCTAACAA	TAACAAAATA	TTAGTTCCTA	AAGTATCAGG 200
	210	220	230	240	250	
Lowy-16L1	201	ATTACAATAC	AGGGTATTTA	GAATACATTT	ACCTGACCCC	AATAAGTTTG 250
hpv1611.gb	201	ATTACAATAC	AGGGTATTTA	GAATACATTT	ACCTGACCCC	AATAAGTTTG 250
hpv1611.mrl	201	ATTACAATAC	AGGGTATTTA	GAATACATTT	ACCTGACCCC	AATAAGTTTG 250
	260	270	280	290	300	
Lowy-16L1	251	GTTTTCCTGA	CACCTCATTT	TATAATCCAG	ATACACAGCG	GCTGGTTTGG 300
hpv1611.gb	251	GTTTTCCTGA	CACCTCATTT	TATAATCCAG	ATACACAGCG	GCTGGTTTGG 300
hpv1611.mrl	251	GTTTTCCTGA	CACCTCATTT	TATAATCCAG	ATACACAGCG	GCTGGTTTGG 300
	310	320	330	340	350	
Lowy-16L1	301	GCCTGTGTAG	GTGTTGAGGT	AGGTCGTGGT	CAGCCATTAG	GTGTGGGCAT 350
hpv1611.gb	301	GCCTGTGTAG	GTGTTGAGGT	AGGTCGTGGT	CAGCCATTAG	GTGTGGGCAT 350
hpv1611.mrl	301	GCCTGTGTAG	GTGTTGAGGT	AGGTCGTGGT	CAGCCATTAG	GTGTGGGCAT 350
	360	370	380	390	400	
Lowy-16L1	351	TAGTGGCCAT	CCTTTATTAA	ATAAATTGGA	TGACACAGAA	AATGCTAGTC 400
hpv1611.gb	351	TAGTGGCCAT	CCTTTATTAA	ATAAATTGGA	TGACACAGAA	AATGCTAGTC 400
hpv1611.mrl	351	TAGTGGCCAT	CCTTTATTAA	ATAAATTGGA	TGACACAGAA	AATGCTAGTC 400
	410	420	430	440	450	
Lowy-16L1	401	CTTATGCAGC	AAATGCAGGT	GTGGATAATA	GAGAATGTAT	ATCTATGGAT 450
hpv1611.gb	401	CTTATGCAGC	AAATGCAGGT	GTGGATAATA	GAGAATGTAT	ATCTATGGAT 450
hpv1611.mrl	401	CTTATGCAGC	AAATGCAGGT	GTGGATAATA	GAGAATGTAT	ATCTATGGAT 450

FIG.2A
SUBSTITUTE SHEET (RULE 26)

3/12

	460	470	480	490	500	
Lowy-16L1	451	TACAAACAAA	CACAATTGTG	TTTAATTGGT	TGCAAAACCAC	CTATAGGGGA 500
hpv1611.gb	451	TACAAACAAA	CACAATTGTG	TTTAATTGGT	TGCAAAACCAC	CTATAGGGGA 500
hpv1611.mr1	451	TACAAACAAA	CACAATTGTG	TTTAATTGGT	TGCAAAACCAC	CTATAGGGGA 500
	510	520	530	540	550	
Lowy-16L1	501	ACACTGGGGC	AAAGGATCCC	CATGTACCAA	TGTTGCAGTA	AATCCAGGTG 550
hpv1611.gb	501	ACACTGGGGC	AAAGGATCCC	CATGTACCAA	TGTTGCAGTA	AATCCAGGTG 550
hpv1611.mr1	501	ACACTGGGGC	AAAGGATCCC	CATGTACCAA	TGTTGCAGTA	AATCCAGGTG 550
	560	570	580	590	600	
Lowy-16L1	551	ATTGTCCACC	ATTAGAGTTA	ATAAACACAG	TTATTCAGGA	TGGTGATATG 600
hpv1611.gb	551	ATTGTCCACC	ATTAGAGTTA	ATAAACACAG	TTATTCAGGA	TGGTGATATG 600
hpv1611.mr1	551	ATTGTCCACC	ATTAGAGTTA	ATAAACACAG	TTATTCAGGA	TGGTGATATG 600
	610	620	630	640	650	
Lowy-16L1	601	GTTGATACTG	GCTTTGGTGC	TATGGACTTT	ACTACATTAC	AGGCTAACAA 650
hpv1611.gb	601	GTTGATACTG	GCTTTGGTGC	TATGGACTTT	ACTACATTAC	AGGCTAACAA 650
hpv1611.mr1	601	GTTGATACTG	GCTTTGGTGC	TATGGACTTT	ACTACATTAC	AGGCTAACAA 650
	660	670	680	690	700	
Lowy-16L1	651	AAGTGAAGTT	CCACTGGATA	TTGTACATC	TATTTGCAAA	TATCCAGATT 700
hpv1611.gb	651	AAGTGAAGTT	CCACTGGATA	TTGTACATC	TATTTGCAAA	TATCCAGATT 700
hpv1611.mr1	651	AAGTGAAGTT	CCACTGGATA	TTGTACATC	TATTTGCAAA	TATCCAGATT 700
	710	720	730	740	750	
Lowy-16L1	701	ATATTAAAT	GGTGCAGAA	CCATATGGCG	ACAGCTTATT	TTTTTATTTA 750
hpv1611.gb	701	ATATTAAAT	GGTGCAGAA	CCATATGGCG	ACAGCTTATT	TTTTTATTTA 750
hpv1611.mr1	701	ATATTAAAT	GGTGCAGAA	CCATATGGCG	ACAGCTTATT	TTTTTATTTA 750
	760	770	780	790	800	
Lowy-16L1	751	CGAAGGGAAC	AAATGTTTGT	TAGACATTTA	TTTAATAGGG	CTGGTACTGT 800
hpv1611.gb	751	CGAAGGGAAC	AAATGTTTGT	TAGACATTTA	TTTAATAGGG	CTGGTACTGT 800
hpv1611.mr1	751	CGAAGGGAAC	AAATGTTTGT	TAGACATTTA	TTTAATAGGG	CTGGTACTGT 800
	810	820	830	840	850	
Lowy-16L1	801	TGGTGAAAAT	GTACCAGACG	ATTTATACAT	TAAAGGCTCT	GGGTCTACTG 850
hpv1611.gb	801	TGGTGAAAAT	GTACCAGACG	ATTTATACAT	TAAAGGCTCT	GGGTCTACTG 850
hpv1611.mr1	801	TGGTGAAAAT	GTACCAGACG	ATTTATACAT	TAAAGGCTCT	GGGTCTACTG 850
	860	870	880	890	900	
Lowy-16L1	851	CAAATTTAGC	CAGTTCAAAT	TATTTTCCTA	CACCTAGTGG	TTCTATGGTT 900
hpv1611.gb	851	CAAATTTAGC	CAGTTCAAAT	TATTTTCCTA	CACCTAGTGG	TTCTATGGTT 900
hpv1611.mr1	851	CAAATTTAGC	CAGTTCAAAT	TATTTTCCTA	CACCTAGTGG	TTCTATGGTT 900

FIG.2B

SUBSTITUTE SHEET (RULE 26)

4/12

		910	920	930	940	950	
Lowy-16L1	901	ACCTCTGATG	CCCAAATATT	CAATAAACCT	TATTGGTTAC	AACGAGCACA	950
hpv1611.gb	901	ACCTCTGATG	CCCAAATATT	CAATAAACCT	TATTGGTTAC	AACGAGCACA	950
hpv1611.mr1	901	ACCTCTGATG	CCCAAATATT	CAATAAACCT	TATTGGTTAC	AACGAGCACA	950
		960	970	980	990	1000	
Lowy-16L1	951	GGGCCACAAT	AATGGCATT	TTTGGGGTAA	CCAACTATTT	GTTACTGTTG	1000
hpv1611.gb	951	GGGCCACAAT	AATGGCATT	TTTGGGGTAA	CCAACTATTT	GTTACTGTTG	1000
hpv1611.mr1	951	GGGCCACAAT	AATGGCATT	TTTGGGGTAA	CCAACTATTT	GTTACTGTTG	1000
		1010	1020	1030	1040	1050	
Lowy-16L1	1001	TTGATACTAC	ACGCAGTACA	AATATGTCAT	TATGTGCTGC	CATATCTACT	1050
hpv1611.gb	1001	TTGATACTAC	ACGCAGTACA	AATATGTCAT	TATGTGCTGC	CATATCTACT	1050
hpv1611.mr1	1001	TTGATACTAC	ACGCAGTACA	AATATGTCAT	TATGTGCTGC	CATATCTACT	1050
		1060	1070	1080	1090	1100	
Lowy-16L1	1051	TCAGAACTA	CATATAAAAA	TACTAATTT	AAGGAGTACC	TACGACATGG	1100
hpv1611.gb	1051	TCAGAACTA	CATATAAAAA	TACTAATTT	AAGGAGTACC	TACGACATGG	1100
hpv1611.mr1	1051	TCAGAACTA	CATATAAAAA	TACTAATTT	AAGGAGTACC	TACGACATGG	1100
		1110	1120	1130	1140	1150	
Lowy-16L1	1101	GGAGGAATAT	GATTTACAGT	TTATTTTCA	ACTGTGCAAA	ATAACCTTAA	1150
hpv1611.gb	1101	GGAGGAATAT	GATTTACAGT	TTATTTTCA	ACTGTGCAAA	ATAACCTTAA	1150
hpv1611.mr1	1101	GGAGGAATAT	GATTTACAGT	TTATTTTCA	ACTGTGCAAA	ATAACCTTAA	1150
		1160	1170	1180	1190	1200	
Lowy-16L1	1151	CTGCAGACGT	TATGACATAC	ATACATTCTA	TGAATTCCAC	TATTTTGGAG	1200
hpv1611.gb	1151	CTGCAGACGT	TATGACATAC	ATACATTCTA	TGAATTCCAC	TATTTTGGAG	1200
hpv1611.mr1	1151	CTGCAGACGT	TATGACATAC	ATACATTCTA	TGAATTCCAC	TATTTTGGAG	1200
		1210	1220	1230	1240	1250	
Lowy-16L1	1201	GACTGGAATT	TTGGTCTACA	ACCTCCCCCA	GGAGGCACAC	TAGAAGATAC	1250
hpv1611.gb	1201	GACTGGAATT	TTGGTCTACA	ACCICCCCCA	GGAGGCACAC	TAGAAGATAC	1250
hpv1611.mr1	1201	GACTGGAATT	TTGGTCTACA	ACCTCCCCCA	GGAGGCACAC	TAGAAGATAC	1250
		1260	1270	1280	1290	1300	
Lowy-16L1	1251	TTATAGGTTT	GTAACCC	AGGCAATTGC	TTGTCAAAAA	CATACACCTC	1300
hpv1611.gb	1251	TTATAGGTTT	GTAACCC	AGGCAATTGC	TTGTCAAAAA	CATACACCTC	1300
hpv1611.mr1	1251	TTATAGGTTT	GTAACATCCC	AGGCAATTGC	TTGTCAAAAA	CATACACCTC	1300
		1310	1320	1330	1340	1350	
Lowy-16L1	1301	CAGCACCTAA	AGAAGATGAT	CCCCTTAAAA	AATACACTTT	TTGGGAAGTA	1350
hpv1611.gb	1301	CAGCACCTAA	AGAAGATGAT	CCCCTTAAAA	AATACACTTT	TTGGGAAGTA	1350
hpv1611.mr1	1301	CAGCACCTAA	AGAAGAT	CCCCTTAAAA	AATACACTTT	TTGGGAAGTA	1350

FIG.2C

SUBSTITUTE SHEET (RULE 26)

5/12

		1360	1370	1380	1390	1400	
Lowy-16L1	1351	AATTTAAAGG	AAAAGTTTTC	TGCAGACCTA	GATCAGTTTC	CTTTAGGACG	1400
hpv1611.gb	1351	AATTTAAAGG	AAAAGTTTTC	TGCAGACCTA	GATCAGTTTC	CTTTAGGACG	1400
hpv1611.mr1	1351	AATTTAAAGG	AAAAGTTTTC	TGCAGACCTA	GATCAGTTTC	CTTTAGGACG	1400
		1410	1420	1430	1440	1450	
Lowy-16L1	1401	CAAATTTTTA	CTACAAGCAG	GATTGAAGGC	CAAACCAAAA	TTTACATTAG	1450
hpv1611.gb	1401	CAAATTTTTA	CTACAAGCAG	GATTGAAGGC	CAAACCAAAA	TTTACATTAG	1450
hpv1611.mr1	1401	CAAATTTTTA	CTACAAGCAG	GATTGAAGGC	CAAACCAAAA	TTTACATTAG	1450
		1460	1470	1480	1490	1500	
Lowy-16L1	1451	GAAAACGAAA	AGCTACACCC	ACCACCTCAT	CTACCTCTAC	AACTGCTAAA	1500
hpv1611.gb	1451	GAAAACGAAA	AGCTACACCC	ACCACCTCAT	CTACCTCTAC	AACTGCTAAA	1500
hpv1611.mr1	1451	GAAAACGAAA	AGCTACACCC	ACCACCTCAT	CTACCTCTAC	AACTGCTAAA	1500
		1510	1520	1530	1540	1550	
Lowy-16L1	1501	CGCAAAAAAC	GTAAGCTGTA				1550
hpv1611.gb	1501	CGCAAAAAAC	GTAAGCTGTA				1550
hpv1611.mr1	1501	CGCAAAAAAC	GTAAGCTGTA				1550

FIG.2D

6/12




FIG.3

7/12

1 2 3 4 5 6 7



FIG.4




FIG. 5

9/12




FIG.6

10/12




FIG.7

11/12

10	20	30	40	50	60
ATGTGGCGGC	CTAGCGACAG	CACAGTATAT	GTGCCTCCTC	CTAACCCCTGT	ATCCAAAGTT
70	80	90	100	110	120
GTTGCCACGG	ATGCTTATGT	TAAACGCACC	AACATATTTT	ATCATGCCAG	CAGTTCTAGA
130	140	150	160	170	180
CTTCTTGCG	TGGGTCATCC	TTATTATTCC	ATAAAAAAGG	TTAACAAAAC	TGTTGTGCCA
190	200	210	220	230	240
AAGGTGTCAG	GATATCAATA	CAGAGTATTT	AAGGTGGTGT	TACCAGATCC	TAACAAATTT
250	260	270	280	290	300
GCATTGCCTG	ACTCGTCTCT	TTTTGATCCC	ACAACACAAC	GTTTGGTATG	GGCATGCACA
310	320	330	340	350	360
GGCCTAGAGG	TGGGCCGGGG	ACAGCCATTA	GGTGTGGGTG	TAAGTGGACA	TCCTTTACTA
370	380	390	400	410	420
AATAAATATG	ATGATGTTGA	AAATTCAGGG	GGTTACGGTG	GTAACCCCTGG	ACAGGATAAC
430	440	450	460	470	480
AGGGTTAATG	TAGGTATGGA	TTATAAACAA	ACACAATTAT	GCATGGTTGG	ATGTGCCCCC
490	500	510	520	530	540
CCTTTGGGCG	AGCATTGGGG	TAAAGGTACA	CAGTGTAGTA	ATACATCTGT	ACAGAATGGT
550	560	570	580	590	600
GACTGCCCCG	CCTTAGAACT	TATTACCAGT	GTTATACAGG	ATGGCGATAT	GGTTGACACA
610	620	630	640	650	660
GGCTTTGGTG	CTATGAATTT	TGCTGATTTG	CAGACCAATA	AATCAGATGT	TCCTCTTGAC
670	680	690	700	710	720
ATATGTGGCA	CTGTATGTAA	ATATCCAGAT	TATTTACAAA	TGGCTGCAGA	CCCATATGGT
730	740	750	760	770	780
GATAGATTAT	TTTTTTATCT	ACGGAAGGAA	CAATGTTTG	CCAGACATTT	TTTTAACAGG
790	800	810	820	830	840
GCTGGTACCG	TGGGGGAACC	TGTGCCTGAT	GATCTTTTAG	TTAAGGGTGG	TAACAATCGC
850	860	870	880	890	900
TCGTCTGTAG	CGAGTAGTAT	ATATGTTTAC	ACCCCAAGCG	GCTCTTTGGT	GTCCTCTGAG
910	920	930	940	950	960
GCACAATTGT	TTAATAAGCC	ATATTGGCTA	CAAAAAGCCC	AGGGACATAA	CAATGGTATT
970	980	990	1000	1010	1020
TGTTGGGGTA	ATCATCTGTT	TGTTACTGTG	GATAGATACCA	CACGCAGTAC	CAACATGACA
1030	1040	1050	1060	1070	1080
TTATGTGCAT	CCGTATCTAA	ATCTGCCACA	TACACCAATT	CTGATTATAA	AGAGTACATG
1090	1100	1110	1120	1130	1140
CGTCATGTGG	AAGAGTTTGA	TTTACAATTT	ATTTTCAAT	TATGTAGCAT	TACATTGTCT
1150	1160	1170	1180	1190	1200
GCTGAAGTAA	TGGCCTATAT	TCACACAATG	AATCCCTCTG	TTCTCGAAGA	CTGGAACCTT
1210	1220	1230	1240	1250	1260
GGGTTATCGC	CTCCCCAAA	TGGTACACTC	GAGGATACCT	ATAGGTATGT	GCAGTCACAG

FIG. 8A
SUBSTITUTE SHEET (RULE 26)

12/12

1270	1280	1290	1300	1310	1320
GCCATTACCT	GTCAAAAGCC	CACTCCTGAA	AAGGAAAAGC	AAGATCCCTA	TAAGGACATG
1330	1340	1350	1360	1370	1380
AGTTTTTGGG	AGGTTAATTT	AAAAGAAAAG	TTTTCTAGTG	AATTGGATCA	GTTTCCTTTG
1390	1400	1410	1420	1430	1440
GGACGCAAGT	TTTTGTTACA	AAGTGGATAT	AGGGGACGGA	CCTCTGCTCG	TACCGGTATT
1450	1460	1470	1480	1490	1500
AAGCGCCCTG	CTGTTTCCAA	ACCCTCTACT	GCCCCTAAAC	GTAAGCGCAC	CAAAACTAAA
1510	1520	1530	1540	1550	1560
AAGTAA.....					

FIG. 8B